Dr. Robert B. Ash
Claim this profileSaint Joseph Hospital - Orange
Studies Lung Cancer
Studies Adenocarcinoma
5 reported clinical trials
22 drugs studied
Affiliated Hospitals
Clinical Trials Robert B. Ash is currently running
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.
Recruiting2 awards Phase 31 criteria
More about Robert B. Ash
Clinical Trial Related6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Robert B. Ash has experience with
- Docetaxel
- Gemcitabine
- Erlotinib Hydrochloride
- Local Consolidation Therapy
- Pemetrexed Disodium
- Intensity-Modulated Radiation Therapy (IMRT)
Breakdown of trials Robert B. Ash has run
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert B. Ash specialize in?
Robert B. Ash focuses on Lung Cancer and Adenocarcinoma. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Robert B. Ash currently recruiting for clinical trials?
Yes, Robert B. Ash is currently recruiting for 2 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Robert B. Ash has studied deeply?
Yes, Robert B. Ash has studied treatments such as Docetaxel, Gemcitabine, Erlotinib Hydrochloride.
What is the best way to schedule an appointment with Robert B. Ash?
Apply for one of the trials that Robert B. Ash is conducting.
What is the office address of Robert B. Ash?
The office of Robert B. Ash is located at: Saint Joseph Hospital - Orange, Orange, California 92868 United States. This is the address for their practice at the Saint Joseph Hospital - Orange.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.